NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024.

Patients should have faster access to newly developed drugs and medicines and the Government is prepared to adopt new ...

It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...

KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint –– Alignment reached with FDA and EMA on key aspects of the ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

CHICAGO, IL / ACCESS Newswire / February 26, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovat ...

The ChAdOx1 viral vector was developed at the University of Oxford and has been investigated as a potential vector for ...

The European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of ...

Paul Chaplin, President and CEO of Bavarian Nordic said, "We are pleased to announce our first collaboration to expand global access to our Chikungunya Vaccine and also our first partnership with ...